Supplemental Table 1 from Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma

2026 Open access

Read full text
Authors: Edward R. Scheffer Cliff, Guido D. Pelaez, Fei Wan, Varun Iyengar, Jihao Zhou, Kevin Chung, Nayef Abdel-Razeq, Jessica Allen, Ajay Major, John Sharp, NARENDRANATH EPPERLA, Patrick W. Gould
+20 more Hua-Jay Jeffery Cherng, Samin Houshyar, Danielle S. Wallace, Ryan C. Lynch, Avyakta Kallam, Matthew Genyeh Mei, Reid W. Merryman, Michelle Fleyshman, Joanna Meehan Rhodes, Adam Kidwell, Timothy S. Fenske, Nikita Malakhov, Erin C. Mulvey, Marcus P. Watkins, Muhamad Alhaj Moustafa, Talal Hilal, Grzegorz S. Nowakowski, Yucai Wang, Pallawi Torka, David A. Russler‐Germain
DOI: 10.1158/1078-0432.31006812
Cited by: 0

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment HER2/EGFR in Cancer Research Cutaneous lymphoproliferative disorders research

Publication details

Publication date
6 January 2026